Цитирование
REMIBRUTINIB SHOWED SUSTAINED EFFICACY AND FAVORABLE SAFETY PROFILE THROUGH WEEK 52 IN CHRONIC INDUCIBLE URTICARIA. // Annals of Allergy, Asthma & Immunology. – URL: https://www.sciencedirect.com/science/article/pii/S1081120626012986?dgcid=rss_sd_all
REMIBRUTINIB SHOWED SUSTAINED EFFICACY AND FAVORABLE SAFETY PROFILE THROUGH WEEK 52 IN CHRONIC INDUCIBLE URTICARIA. Annals of Allergy, Asthma & Immunology. https://www.sciencedirect.com/science/article/pii/S1081120626012986?dgcid=rss_sd_all
“REMIBRUTINIB SHOWED SUSTAINED EFFICACY AND FAVORABLE SAFETY PROFILE THROUGH WEEK 52 IN CHRONIC INDUCIBLE URTICARIA.” Annals of Allergy, Asthma & Immunology.
@article{article93202,
title = {REMIBRUTINIB SHOWED SUSTAINED EFFICACY AND FAVORABLE SAFETY PROFILE THROUGH WEEK 52 IN CHRONIC INDUCIBLE URTICARIA},
journal = {Annals of Allergy, Asthma \& Immunology},
url = {https://www.sciencedirect.com/science/article/pii/S1081120626012986?dgcid=rss_sd_all}
}